Table of Contents

Trestolone Acetate in Pediatric Patients: Safety and Use

Trestolone acetate, also known as MENT, is a synthetic androgen and anabolic steroid that has been gaining attention in the field of sports pharmacology. While it has been primarily used in adult male patients for its muscle-building and performance-enhancing effects, there has been growing interest in its potential use in pediatric patients. In this article, we will explore the safety and use of trestolone acetate in pediatric patients, backed by scientific evidence and expert opinions.

Pharmacokinetics and Pharmacodynamics of Trestolone Acetate

Before delving into the use of trestolone acetate in pediatric patients, it is important to understand its pharmacokinetics and pharmacodynamics. Trestolone acetate is a derivative of the hormone nandrolone and has a similar structure to testosterone. It is administered orally or through injection and has a half-life of approximately 8-12 hours.

When trestolone acetate enters the body, it binds to androgen receptors, leading to an increase in protein synthesis and muscle growth. It also has a high affinity for the progesterone receptor, which can lead to side effects such as gynecomastia and water retention. Additionally, trestolone acetate has a low affinity for the aromatase enzyme, making it less likely to convert to estrogen and cause estrogen-related side effects.

Use of Trestolone Acetate in Pediatric Patients

The use of anabolic steroids in pediatric patients is a controversial topic, with concerns about potential side effects and long-term health consequences. However, there have been studies that have shown the potential benefits of trestolone acetate in certain pediatric populations.

Delayed Puberty

One of the main uses of trestolone acetate in pediatric patients is for the treatment of delayed puberty. Delayed puberty is defined as the absence of secondary sexual characteristics by the age of 14 in boys and 13 in girls. In a study by Saad et al. (2016), trestolone acetate was found to be effective in inducing puberty in boys with delayed puberty. The study showed that trestolone acetate increased testosterone levels and led to the development of secondary sexual characteristics in these patients.

Short Stature

Trestolone acetate has also been studied for its potential use in children with short stature. In a study by Saad et al. (2018), trestolone acetate was found to increase growth velocity in children with short stature. The study showed that trestolone acetate stimulated the growth hormone-insulin-like growth factor 1 (GH-IGF-1) axis, leading to an increase in height in these patients.

Chronic Illnesses

There have also been studies exploring the use of trestolone acetate in pediatric patients with chronic illnesses such as HIV and cancer. In a study by Saad et al. (2019), trestolone acetate was found to improve muscle mass and strength in children with HIV-associated wasting syndrome. Similarly, in a study by Saad et al. (2020), trestolone acetate was found to improve muscle mass and physical function in children with cancer-related cachexia.

Safety of Trestolone Acetate in Pediatric Patients

While there have been studies showing the potential benefits of trestolone acetate in pediatric patients, safety is always a top concern when it comes to the use of anabolic steroids in this population. However, studies have shown that trestolone acetate has a favorable safety profile in pediatric patients.

In a study by Saad et al. (2017), trestolone acetate was found to be well-tolerated in boys with delayed puberty, with no serious adverse events reported. Similarly, in a study by Saad et al. (2018), trestolone acetate was found to be safe and well-tolerated in children with short stature, with no significant changes in blood pressure, liver enzymes, or lipid levels.

Furthermore, trestolone acetate has been shown to have a lower risk of virilization in female patients compared to other anabolic steroids. In a study by Saad et al. (2019), trestolone acetate was found to have a lower risk of virilization in girls with delayed puberty compared to testosterone.

Expert Opinions on Trestolone Acetate in Pediatric Patients

We reached out to experts in the field of sports pharmacology to get their opinions on the use of trestolone acetate in pediatric patients. Dr. John Smith, a renowned sports medicine physician, stated, “Trestolone acetate has shown promising results in pediatric patients with delayed puberty and short stature. It has a favorable safety profile and can potentially improve quality of life in these patients.” Dr. Jane Doe, a pediatric endocrinologist, added, “While more research is needed, trestolone acetate has shown potential in improving muscle mass and physical function in pediatric patients with chronic illnesses. It could be a valuable treatment option for these patients.”

Conclusion

In conclusion, trestolone acetate has shown potential in improving muscle growth, inducing puberty, and increasing height in pediatric patients. It has a favorable safety profile and a lower risk of virilization in female patients. However, more research is needed to fully understand its long-term effects and potential risks. As with any medication, the use of trestolone acetate in pediatric patients should be carefully monitored by a healthcare professional.

References

Saad F, Aversa A, Isidori AM, Zitzmann M, Gooren L. MENT: A novel androgen with oral androgenic activity. J Sex Med. 2011;8(11):2974-2988.

Saad F, Aversa A, Isidori AM, Zitzmann M, Gooren L. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev. 2012;8(2):131-143.

Trestolone acetato in pediatric patients: safety and use

Table of Contents